US Launches New Trade Investigation Into Vietnam Over Intellectual Property Concerns 
New World Screwworm Found Near U.S. Border Raises Threat to Cattle Industry and Beef Prices 
Wall Street Hits New Highs as U.S.-Iran Ceasefire Talks Boost Market Sentiment 
Elon Musk Explores Possible Tesla-SpaceX Merger Amid Growing AI Investments 
SK Hynix Joins $1 Trillion Club as AI Chip Demand Fuels Stock Surge 
DOJ Investigates Group Linked to Reid Hoffman Over E. Jean Carroll Lawsuit Funding 
MongoDB Q1 FY2027 Earnings Beat Expectations, Raises Full-Year Outlook 
SQM Q1 Profit More Than Doubles as Lithium Prices Surge 
HP Q2 2026 Earnings Beat Expectations Despite Memory Chip Pressure 
Iran-U.S. Nuclear Talks Remain Unresolved as Strait of Hormuz Risks Keep Markets on Edge 
Meta Subscription Push Could Add Billions in Recurring Revenue, Says Rosenblatt 
Xiaomi Shares Drop After Weak Q1 Earnings Amid Rising Smartphone Costs 
Dow Hits Record High as Healthcare and Consumer Stocks Lead Wall Street Rally 
Oil Prices Jump After New U.S. Strikes on Iran Raise Supply Concerns 
Australia Sues 3M for Over A$2 Billion Over PFAS Firefighting Foam Contamination 
Kentucky School District Secures $27 Million in Social Media Addiction Lawsuit Settlements 
SpaceX IPO Could Become Largest in History with $1.8 Trillion Valuation Target 
Celltrion Inc., a biopharmaceutical company headquartered in Incheon, South Korea, is merging with its Celltrion Healthcare subsidiary in an effort to strengthen its business synergy or combined effort. The biosimilar producer and its biosimilar marketing unit are set to be consolidated this year.
Seo Jung Jin, Celltrion Group’s chairman, said on Thursday, Aug. 17, that once Celltrion is incorporated with Celltrion Healthcare, the newly-formed entity will also take in Celltrion Pharma. The chairman said this integration will eventually happen later but did not provide an exact time frame. After all the mergings, Celltrion, Celltrion Healthcare, and the company’s chemical pharma producer will work together as one.
According to The Korea Times, Celltrion revealed its plan to acquire Celltrion Healthcare during the company’s recent regulatory filing. The changes will also entail the issuance of new shares of Celltrion to shareholders of Celltrion Healthcare, and the merger ratio is expected to stand at 1:0.4492620.
It was mentioned that the Celltrion chairman holds a 95% stake in Celltrion Holdings which in turn holds a 20.02% stake in Celltrion. The holdings also have a 35.54% stake in Celltrion Healthcare and a 54.96% stake in Celltrion Pharm.
"Celltrion is expected to complete the merger of Celltrion Healthcare by the end of the year, followed by the next merger with Celltrion Pharm in the next six months," Seo Jung Jin shared during an online conference.
The Celltrion Group said it will merge the mentioned companies, but the plan still needs the approval of shareholders. This may be completed on October 23 at the shareholders' meeting. Celltrion and Celltrion Healthcare will eventually be dissolved after the merger.
To date, while the merger is still being processed, The Korea Herald reported that Celltrion is focusing on producing and developing bio-pharmaceutical products while Celltrion Healthcare is working more on selling these products.
Photo by: Celltrion Press Room
